← Back to Search

Fiber Supplement

Glucomannan for Obesity

Phase 4
Waitlist Available
Research Sponsored by ProMedica Health System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed at 2, 4, 8, and 12 week intervals
Awards & highlights

Study Summary

Glucomannan is a dietary supplement that has been marketed for weight loss. There is some research that supports this claim but more research is necessary. This is research study is being conducted to determine if the dietary supplement glucomannan is effective for weight loss in adults greater than 18 years of age who are overweight. Participants will be randomized in a 1:1 manner (like the flip of a coin) to receive either glucomannan 575 milligrams, 2 capsules three times daily or placebo, 2 capsules three times daily. The study will last for 12 weeks. At the start of the study participants will be asked questions about current medications and diet/exercise regimen, a weight and height will be obtained, and they will be given a one-month's supply of study supplement. An investigator will call each participant after they have been taking the supplement for 2 weeks to ensure that the participant is tolerating the supplement and answer any questions. Throughout the study, participants will be required to follow-up with investigators in the office every 4 weeks (a total of 3 follow-up appointments). Every 4 weeks, the investigators will weigh participants, count the leftover capsules from the previous month, and ask about any adverse effects you may be experiencing. At the conclusion of the study, a final weight will be compared with the baseline weight to determine if the medication had an effect on weight loss.

Eligible Conditions
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed at 2, 4, 8, and 12 week intervals
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed at 2, 4, 8, and 12 week intervals for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Weight
Secondary outcome measures
Side Effects

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: GlucomannanActive Control1 Intervention
Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day.
Group II: PlaceboPlacebo Group1 Intervention
Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.

Find a Location

Who is running the clinical trial?

ProMedica Health SystemLead Sponsor
13 Previous Clinical Trials
720 Total Patients Enrolled
Ashley M Parrott, PharmDStudy ChairThe Toledo Hospital
Steve Smith, MS, RPhStudy DirectorThe Toledo Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby May 2025